Company intelligence / Profile preview

Atrion

Ownership: Public · ATRI
Development stage: Commercial

Overview

Atrion develops and manufactures FDA-regulated medical devices for cardiovascular surgery (notably the MPS Myocardial Protection System), infusion therapy valves and components used in oncology/dialysis drug delivery systems, ophthalmic balloon catheters for tear duct procedures, and a range of OEM fluid management products. The company reported $169.3 million in revenue for 2023 with recent growth in cardiovascular device sales after resolving supply chain issues. No clinical trial results as it does not develop therapeutics.

Therapeutic areas: OphthalmologyOncologyCardiovascular
Modalities: Device
Industry: Surgical Medical Devices

Partnerships

Not specifically disclosed; supplies to major medical device/pharma/biotech OEMs as contract manufacturer/OEM supplier

Financials

Market cap: $809.4M
Total revenue: $48.8M
Enterprise value: $791.9M

Beyond the preview

Go deeper on Atrion.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Atrion.

Explore the full profile